The relatively high frequency and clinical impact of ASXL1 c.1934dupG mutation in MPN, CMML, MDS/AML cases makes ASXL1 a good candidate for disease monitoring using ultrasensitive detection by NGS that could be applied to DNA derived from bone marrow or plasma (cftDNA)[29]. This evidence concerns the gene ASXL1 and chronic myelomonocytic leukemia.